基于微信的干预治疗2型糖尿病患者的血糖控制:多中心随机对照试验
Chuanfen Zheng1, Xiong Dou1, Xiaotao Xiong1
1Department of Health Education, College of Preventive Medicine, Army Medical University, 30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China, 86 02368771579.
JMIR mHealth and uHealth
|February 20, 2026
概括
一个基于微信的健康教育计划显著改善了中国2型糖尿病患者的血糖控制. 这种数字干预在两年内证明了持续的益处,为初级保健中糖尿病管理提供了可扩展的解决方案.
科学领域:
- 数字健康数字健康
- 公共卫生 公共卫生
- 内分泌学 在内分泌学.
背景情况:
- 中国面临着一个严重的糖尿病流行病,而血糖控制不理想.
- 传统干预措施在可扩展性和在初级保健中接触弱势群体方面存在局限性.
研究的目的:
- 评估基于微信的健康教育工具,以改善社区居住的2型糖尿病患者的血糖控制.
- 与传统方法相比,评估数字健康干预的有效性.
主要方法:
- 一个多中心随机对照试验,涉及600名2型糖尿病成年人.
- 参与者被分配到为期12周的基于微信的干预或接受传统健康教育的对照组.
- 主要结局包括12周和2年随访时血红蛋白A1c (HbA1c) 和空腹血糖 (FBG) 的变化.
主要成果:
- 与对照组相比,微信干预组显示出明显更大的HbA1c降低和FBG改善.
- 在糖尿病持续时间<10年,教育程度较低,收入较低的患者中,益处尤为明显.
- 在2年的随访期内,改善的血糖控制得到了持续.
结论:
- 基于微信的健康教育对于改善2型糖尿病的初级保健机构的血糖控制是有效的.
- 数字化方法显示了可扩展的糖尿病管理的希望,尽管需要进一步研究持续的疗效和可行性.
相关概念视频
Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Diabetes Mellitus: Type 2 and Gestational
5.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
712
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
712
Hormones Regulating Blood Glucose
7.2K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
7.2K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
621
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
621
Diabetes Mellitus: Overview and Type I Subtype
5.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.6K

